TW202227131A - 帕金森氏症之治療 - Google Patents

帕金森氏症之治療 Download PDF

Info

Publication number
TW202227131A
TW202227131A TW110133867A TW110133867A TW202227131A TW 202227131 A TW202227131 A TW 202227131A TW 110133867 A TW110133867 A TW 110133867A TW 110133867 A TW110133867 A TW 110133867A TW 202227131 A TW202227131 A TW 202227131A
Authority
TW
Taiwan
Prior art keywords
individual
disease
parkinson
prasemumab
ser
Prior art date
Application number
TW110133867A
Other languages
English (en)
Chinese (zh)
Inventor
吉恩那羅 帕葛諾
瓦格奈 薩果
Original Assignee
愛爾蘭商普羅佘納生物科技有限公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商普羅佘納生物科技有限公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 愛爾蘭商普羅佘納生物科技有限公司
Publication of TW202227131A publication Critical patent/TW202227131A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW110133867A 2020-09-10 2021-09-10 帕金森氏症之治療 TW202227131A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202063076916P 2020-09-10 2020-09-10
US202063076915P 2020-09-10 2020-09-10
US202063076913P 2020-09-10 2020-09-10
US63/076,915 2020-09-10
US63/076,916 2020-09-10
US63/076,913 2020-09-10
US202163158191P 2021-03-08 2021-03-08
US63/158,191 2021-03-08

Publications (1)

Publication Number Publication Date
TW202227131A true TW202227131A (zh) 2022-07-16

Family

ID=80629905

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110133867A TW202227131A (zh) 2020-09-10 2021-09-10 帕金森氏症之治療

Country Status (10)

Country Link
US (2) US12084491B2 (enExample)
EP (1) EP4211162A4 (enExample)
JP (1) JP2023541048A (enExample)
KR (1) KR20230086674A (enExample)
AU (1) AU2021338781A1 (enExample)
CR (1) CR20230121A (enExample)
IL (1) IL301039A (enExample)
MX (1) MX2023002851A (enExample)
TW (1) TW202227131A (enExample)
WO (1) WO2022056209A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
US20240279316A1 (en) * 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
CN117409969B (zh) * 2023-11-13 2026-04-03 深圳市臻络科技有限公司 帕金森病运动功能评估方法、装置及电子设备

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7981058B2 (en) 2004-03-12 2011-07-19 The Trustees Of Dartmouth College Intelligent wearable monitor systems and methods
US20060122472A1 (en) 2004-09-28 2006-06-08 Pullman Seth L System and method for clinically assessing motor function
US8702629B2 (en) 2005-03-17 2014-04-22 Great Lakes Neuro Technologies Inc. Movement disorder recovery system and method for continuous monitoring
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
JP5251270B2 (ja) 2008-06-04 2013-07-31 三菱化学株式会社 パーキンソン病の評価装置
RU2540470C9 (ru) * 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
US20100076348A1 (en) 2008-09-23 2010-03-25 Apdm, Inc Complete integrated system for continuous monitoring and analysis of movement disorders
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
CN101963919A (zh) 2009-07-24 2011-02-02 鸿富锦精密工业（深圳）有限公司 进程管理系统
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9924899B2 (en) 2013-09-09 2018-03-27 Alexis Pracar Intelligent progression monitoring, tracking, and management of parkinson's disease
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
JP6595490B2 (ja) 2014-02-04 2019-10-23 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター 身体固定センサを使用してパーキンソン病の診断または予後を提供する方法およびシステム
US20180126158A1 (en) 2016-08-22 2018-05-10 Lyriq, Llc Systems and Methods for Functional Restoration and Rehabilitation of Posture, Gait and Movement
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
EP3833435B1 (en) 2018-08-09 2025-09-24 F. Hoffmann-La Roche AG Determination of parkinson's disease
KR20230154249A (ko) 2021-03-08 2023-11-07 프로테나 바이오사이언시즈 리미티드 파킨슨 질환의 치료

Also Published As

Publication number Publication date
US12084491B2 (en) 2024-09-10
US20220098291A1 (en) 2022-03-31
WO2022056209A1 (en) 2022-03-17
US20250188158A1 (en) 2025-06-12
MX2023002851A (es) 2023-03-22
CR20230121A (es) 2023-07-26
EP4211162A4 (en) 2025-04-30
EP4211162A1 (en) 2023-07-19
JP2023541048A (ja) 2023-09-27
AU2021338781A1 (en) 2023-03-30
IL301039A (en) 2023-05-01
KR20230086674A (ko) 2023-06-15

Similar Documents

Publication Publication Date Title
US12600787B2 (en) Methods for the treatment of thyroid eye disease
US12084491B2 (en) Treatment of Parkinson's disease
US20240158516A1 (en) Methods for the treatment of thyroid eye disease
US20210253686A1 (en) Methods for the treatment of scleroderma and related conditions
AU2021200093B2 (en) Treatment and prevention of alzheimer's disease (ad)
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
KR20130100973A (ko) 항-ｖｅｇｆ 요법을 사용하는 혈관화 색소 상피 박리의 치료
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
US8012478B2 (en) Use of anti-IL-20 antibody for treating stroke
CN118055767A (zh) 新颖的组合施用
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
AU2020263709A1 (en) Method of treatment
WO2025036488A9 (en) Methods of treating age-related macular degeneration and diabetic macular edema
RU2848183C1 (ru) Лечение болезни паркинсона
US20240043545A1 (en) Methods and compositions for treatment of thyroid eye disease
JP2025524736A (ja) 体位性頻脈症候群を処置するための組成物及び方法
CN116802208A (zh) 帕金森氏病的治疗
CN106659736A (zh) 阿尔茨海默病(ad)的治疗和预防
JPWO2019093262A1 (ja) 腸内環境制御による近視抑制
CN117440821A (zh) 用ngf治疗神经性角膜疼痛
JP2023532882A (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
WO2025192737A1 (ja) 脈絡膜菲薄化抑制剤
CN115812079A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗